Kura Oncology Inc. (NASDAQ:KURA) saw unusually-strong trading volume on Monday . Approximately 436,225 shares changed hands during trading, a decline of 5% from the previous session’s volume of 457,930 shares.The stock last traded at $4.40 and had previously closed at $5.19.

A number of equities research analysts have recently issued reports on KURA shares. Zacks Investment Research raised shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a report on Wednesday, July 13th. Citigroup Inc. dropped their target price on shares of Kura Oncology from $19.00 to $12.00 and set a “buy” rating for the company in a report on Monday, March 21st. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $16.00 target price on shares of Kura Oncology in a report on Tuesday, June 21st.

The firm’s 50-day moving average is $3.08 and its 200 day moving average is $3.87. The stock’s market cap is $80.95 million.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, May 11th. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. Equities analysts expect that Kura Oncology Inc. will post ($1.70) earnings per share for the current year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.